| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 1.6 | 2.2 |
| Net income | -26.6 | -27.5 |
| EPS (diluted, $ a share) | $-0.25 | $-0.30 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -26.9% |
|---|
10-Q filed with the SEC, NASDAQ: CRBU. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Caribou Biosciences, Inc.: key numbers
- Share price
- $0.3407Close, Nov 17
- Market cap
- $36.8M
- Shares outstanding
- 108.04MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Caribou Biosciences, Inc.
All →Caribou Biosciences Financial Results
Caribou Biosciences reported Q3 2026 financial results, including a GAAP net loss of $26.6 million on revenue of $1.6 million. The company also highlighted its October 2026 decision to discontinue clinical trials for vispa-cel and CB-011 and reduce its workforce while exploring strategic alternatives such as a merger or acquisition.
- Term
- Q3 2026
Caribou Biosciences Business Update
Caribou Biosciences is exploring strategic alternatives and implementing a restructuring plan that includes discontinuing its allogeneic CAR-T cell therapy programs, vispa-cel and CB-011. The company is conducting a substantial workforce reduction and expects to incur restructuring charges between $15 million and $19 million, primarily for severance and clinical trial wind-down costs.